Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Active Comparator Control Clear all
Not yet recruiting Phase 2 Interventional

Semaglutide for Low Back Pain

NCT07731256
View directory record Official record
Conditions
Lower Back Pain, Obesity (BMI>30), Chronic Lower Back Pain, glp1 Agonist
Interventions
Semaglutide (administered by PDS290 pen-injector), Placebo (administered by PDS290 pen-injector)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
2
States / cities
Birmingham, Alabama • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 11, 2026, 5:01 PM EDT
Completed Not applicable Interventional

Soy Formula Feedings in Healthy, Term Infants

NCT02456831
View directory record Official record
Conditions
Gastrointestinal Tolerance
Interventions
Experimental Infant Formula 1, Experimental Infant Formula 2, Experimental Infant Formula 3, Active Comparator: Control Infant Formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
2 Weeks to 9 Weeks
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1994
U.S. locations
7
States / cities
Little Rock, Arkansas • Aurora, Illinois • Owensboro, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Sep 11, 2026, 5:01 PM EDT
Completed Phase 1 Interventional

Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer

NCT01870037
View directory record Official record
Conditions
Overactive Bladder
Interventions
Placebo (PBS-20% sucrose), hMaxi-K
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Garden City, New York • New York, New York • Poughkeepsie, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 11, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

NCT05794581
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
CT-868, Placebo, Victoza
Drug
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 11, 2026, 5:01 PM EDT
Terminated Phase 2 Interventional Results available

Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease

NCT02162979
View directory record Official record
Conditions
Parkinson's Disease
Interventions
sildenafil, Placebo
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Sep 11, 2026, 5:01 PM EDT
Terminated Phase 2 Interventional Results available

Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis

NCT00995449
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
KB003, Placebo Comparator
Biological · Other
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
11
States / cities
Stanford, California • Westlake Village, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 11, 2026, 5:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance

NCT02254317
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
0 mg placebo, 300 mg GSE, 600 mg GSE, 900 mg GSE
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
40 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 11, 2026, 5:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lean Body Mass Response to Higher-protein Diets During Winter Military Training

NCT02327208
View directory record Official record
Conditions
Body Weight
Interventions
Control, Protein, Carbohydrate
Dietary Supplement
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 11, 2026, 5:01 PM EDT
Not yet recruiting Not applicable Interventional

Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder

NCT07282678
View directory record Official record
Conditions
Depression - Major Depressive Disorder, Transcranial Alternating Current Stimulation
Interventions
Closed-loop tACS, Sham Comparator
Device
Lead sponsor
Pulvinar Neuro, LLC
Industry
Eligibility
22 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 11, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Results available

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03127514
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Diseases, Neurodegenerative Diseases, Spinal Cord Diseases, TDP-43 Proteinopathies, Nervous System Diseases, Central Nervous System Diseases
Interventions
AMX0035, Placebo
Drug · Other
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
25
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 11, 2026, 5:01 PM EDT
Completed Not applicable Interventional

A Multicenter RCT to Investigate the Treatment of Double (Bilateral) Mandibular Fractures

NCT02341443
View directory record Official record
Conditions
Mandibular Fractures
Interventions
Implants
Procedure
Lead sponsor
AO Clinical Investigation and Publishing Documentation
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
New York, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 11, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis

NCT00750139
View directory record Official record
Conditions
Tinea Pedis, Athlete's Foot
Interventions
NAFT-500, Placebo 2-weeks, Naftin 1%, Placebo 4-weeks
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
707 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Sep 11, 2026, 5:01 PM EDT
Not yet recruiting Phase 2 Interventional

Daridorexant for People With Insomnia and Alcohol Use Disorder Study

NCT07701928
View directory record Official record
Conditions
Alcohol Use Disorder, Insomnia
Interventions
Daridorexant, Placebo, Brief Counseling, MEMS and Medication Accounting, Contingency Management for Medication Adherence
Drug · Behavioral · Device
Lead sponsor
Sterling McPherson
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 11, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Results available

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

NCT05055128
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
X842, X842 Dummy, Lansoprazole, Lansoprazole Dummy
Drug
Lead sponsor
Cinclus Pharma Holding AB
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 11, 2026, 5:01 PM EDT
Completed Phase 4 Interventional Results available

Helping Those With Mental Illness Quit Smoking

NCT01783912
View directory record Official record
Conditions
Smoking, Nicotine Dependence, Mental Disorders
Interventions
Cognitive / Motivational Individual Sessions, Attention Control Individual Sessions, Nicotine Patch, Group Curriculum
Behavioral · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 11, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

NCT04115319
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP363856, quetiapine XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
18
States / cities
Cerritos, California • Oakland, California • Oceanside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 11, 2026, 5:01 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Precision Dosing of Metformin in Youth With T2D

NCT06120881
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
10 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Oakland, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 11, 2026, 5:01 PM EDT
Completed Phase 4 Interventional Results available

Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

NCT00351611
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Lyrica (pregabalin), placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
103
States / cities
Mobile, Alabama • Northport, Alabama • Tuscaloosa, Alabama + 57 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 11, 2026, 5:01 PM EDT
Completed Not applicable Interventional Results available

CPAP vs ASV for Insomnia

NCT02365064
View directory record Official record
Conditions
Insomnia, Sleep-Disordered Breathing
Interventions
AirCurve 10 ASV
Device
Lead sponsor
ResMed
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Sep 11, 2026, 5:01 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome

NCT01873703
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
pracinostat, Placebo, Azacitidine
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
24
States / cities
Mobile, Alabama • La Jolla, California • Denver, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Sep 11, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Results available

Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients

NCT01601236
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Repository Corticotropin Injection, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
10
States / cities
Roseville, California • Cooper City, Florida • Miami Springs, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 11, 2026, 5:01 PM EDT
Not yet recruiting Not applicable Interventional

MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma

NCT07541404
View directory record Official record
Conditions
Subdural Hematoma
Interventions
NeoCast Embolic System, Onyx LES, an FDA-Approved Commercial Liquid Embolic
Device
Lead sponsor
Arsenal Medical, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 11, 2026, 5:01 PM EDT
Completed Not applicable Interventional

Efficacy of Brief Acceptance and Commitment Therapy (ACT) for Perinatal Anxiety

NCT03837392
View directory record Official record
Conditions
Post Partum Depression, Perinatal Depression, Post Partum Anxiety, Perinatal Anxiety
Interventions
Baseline Assessment (18-26 weeks pregnant), Online Intervention and Phone Coaching Interventions, Follow Up Assessments: 34-36 weeks pregnant and 4-week postpartum, Follow Up Assessments: 8 weeks postpartum
Diagnostic Test · Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Sep 11, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema

NCT05151744
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Vamikibart, Ranibizumab, Sham Procedure
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Arcadia, California • Torrance, California • Walnut Creek, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 11, 2026, 5:01 PM EDT